Robson W L, Leung A K
Children's Hospital, Greenville, South Carolina.
Adv Pediatr. 1994;41:163-94.
Henoch-Schönlein purpura is a fairly common pediatric disorder. The role of immunosuppression in the treatment of HSP continues to be controversial and awaits a multicenter controlled trial. The prognosis for the majority of patients is very good. Less than 2% of patients develop a serious complication associated with long-term morbidity. The most common serious complication is end-stage kidney disease, which may develop late in the disease after the symptoms from other organ systems have resolved. Patients with HSP should be carefully followed for several years to look for evidence of late renal involvement, and those patients who develop renal involvement should be followed regularly throughout their lifetime.
过敏性紫癜是一种相当常见的儿科疾病。免疫抑制在过敏性紫癜治疗中的作用仍存在争议，有待多中心对照试验验证。大多数患者的预后非常好。不到2%的患者会出现与长期发病相关的严重并发症。最常见的严重并发症是终末期肾病，可能在疾病后期其他器官系统症状缓解后出现。过敏性紫癜患者应密切随访数年，以寻找晚期肾脏受累的证据，而那些出现肾脏受累的患者应在其一生中定期随访。
